The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Milanović, Dušan ^a   Braun, Friederike ^a   Weber, Wolfgang ^a   Grosu, Anca L ^a   Behe, Martin ^b   Niedermann, Gabriele ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; VADIMEZAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CELL LINE, TUMOR; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; PACLITAXEL; POSITRON-EMISSION TOMOGRAPHY; TUMOR BURDEN; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862155604     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-242     Document Type: Article

References (37)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001, 344:114-123. 10.1056/NEJM200101113440207, 11150363.
2. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006, 24:2563-2569. 10.1200/JCO.2005.04.5963, 16735709.
3. Wong ET, Brem S. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw 2008, 6:515-522.
4. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848. 10.1038/359845a0, 1279432.
5. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009, 14:1131-1138. 10.1634/theoncologist.2009-0121, 19897538.
6. Rehman F, Rustin G. ASA404: update on drug development. Expert Opin Investig Drugs 2008, 17:1547-1551. 10.1517/13543784.17.10.1547, 18808313.
7. Browne WL, Wilson WR, Baguley BC, Ching LM. Suppression of serum tumour necrosis factor- by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumor activity of 5,6-dimethylxanthenone-4-acetic acid. Anticancer Res 1998, 18:4409-4413.
8. Wang LC, Thomsen L, Sutherland R, Reddy CB, Tijono SM, Chen CJ, Angel CE, Dunbar PR, Ching LM. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). Neoplasia 2009, 11:793-803. 2713591, 19649209.
9. Baguley BC, Zhuang L, Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicines: relation to vascular effects. Oncol Res 1997, 9:55-60.
10. Thomsen LL, Baguley BC, Wilson WR. Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumor cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1992, 3:151-155.
11. Cao Z, Baguley BC, Ching LM. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res 2001, 61:1517-1521.
12. Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003, 51(1):43-52. 10.1007/s00280-002-0529-0, 12497205.
13. Fuchs DA, Johnson RK. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 1978, 62:1219-1222.
14. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, Braguer D. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005, 65:2433-2440. 10.1158/0008-5472.CAN-04-2624, 15781659.
15. Dorsey JF, Mintz A, Tian X, Dowling ML, Plastaras JP, Dicker DT, Kao GD, El-Deiry WS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol Cancer Ther 2009, 8:3285-3295. 10.1158/1535-7163.MCT-09-0415, 19996278.
16. Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 2008, 14:3416-3426. 10.1158/1078-0432.CCR-07-1824, 18519772.
17. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006, 12:5659-5667. 10.1158/1078-0432.CCR-06-0368, 17020967.
18. Kim JS, Lee JS, Im KC, Kim SJ, Kim SY, Lee DS, Moon DH. Performance measurement of the microPET focus 120 scanner. J Nucl Med 2007, 48:1527-1535. 10.2967/jnumed.107.040550, 17704248.
19. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003, 2:131-137. 10.1162/153535003322556877, 14649056.
20. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumors. Nat Rev Neurosci 2007, 8:610-622.
21. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62. 10.1126/science.1104819, 15637262.
22. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005, 5:423-435. 10.1038/nrc1628, 15928673.
23. Fitzpatrick FA, Wheeler R. The immunopharmacology of paclitaxel (taxol), docetaxel (Taxotere), and related agents. Int Immunopharmacol 2003, 3:1699-1714. 10.1016/j.intimp.2003.08.007, 14636822.
24. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002, 99:1-6. 10.1002/ijc.10316, 11948484.
25. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching LM. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 1999, 59:633-638.
26. Ching LM, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 2004, 90:906-910. 10.1038/sj.bjc.6601606, 2410181, 14970872.
27. Ching L-M, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 2002, 86:1937-1942. 10.1038/sj.bjc.6600368, 2375421, 12085190.
28. Oehler C, O'Donoghue JA, Russell J, Zanzonico P, Lorenzen S, Ling CC, Carlin S. 18 F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. J Nucl Med 2011, 52:437-444. 10.2967/jnumed.110.081372, 3394183, 21321262.
29. Benigni F, Atsumi T, Calandra T, Metz C, Echtenacher B, Peng T, Bucala R. The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest 2000, 106:1291-1300. 10.1172/JCI9900, 381433, 11086030.
30. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME, Weber WA. Impact of animal handling on the results of 18 F-FDG PET studies in mice. J Nucl Med 2006, 47:999-1006.
31. Seshadri M, Ciesielski MJ. MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas. J Cereb Blood Flow Metab 2009, 29:1373-1382. 10.1038/jcbfm.2009.68, 2902992, 19458603.
32. Seshadri M, Bellnier DA, Cheney RT. Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors. Int J Radiat Oncol Biol Phys 2008, 72:1198-1207. 10.1016/j.ijrobp.2008.07.043, 2582978, 18954713.
33. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003, 4:141-148. 10.1016/S1470-2045(03)01018-0, 12623359.
34. Kelland LR. Targeting established tumor vasculature: a novel approach to cancer treatment. Curr Cancer Ther Rev 2005, 1:1-9.
35. Zhao L, Ching LM, Kestell P, Baguley BC. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. Clin Cancer Res 2003, 9:6545-6550.
36. McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008, 99:2006-2012. 10.1038/sj.bjc.6604808, 2607218, 19078952.
37. Lara PN, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:2965-2971. 10.1200/JCO.2011.35.0660, 21709202.